Clinical trials: Secondary Immune Deficiency, open to volunteers
Hiv, Alcohol Drinking
HIV and Alcohol Research Center Focused on Polypharmacy (HARP) Pilot 2 (2nd HARP Pilot Intervention)
The focus of this pilot will be on falls and neurocognitive symptoms, and the impact of alcohol, cannabis use, and medications on these outcomes.
- Conditions
- Hiv, Alcohol Drinking, Fall, Cannabis Use
- Trial name
- HARP (NCT06513819)
- Testing
- Information Motivation Behavioral and Motivational Interviewing (IMB-MI) technique
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Yale University
Chronic Lymphocytic Leukaemia (CLL), Multiple Myeloma (MM)
Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematological Patients With Secondary Immunodeficiency (SID) Across the Treatment Trajectory - The PRO SID Project
The goal of this observational study is to improve the treatment of hematological patients with secondary immunodeficiency (SID) by developing a patient-reported outcome (PRO) instrument to detect clinically diagnosed infections.
- Conditions
- Chronic Lymphocytic Leukaemia (CLL), Multiple Myeloma (MM), Secondary Immunodeficiency (SID)
- Trial name
- PRO-SID (NCT06821880)
- Where
- 5 sites in Austria, Germany
- Volunteers
- 120 people
- Sponsor
- Medical University Innsbruck
Haematological Malignancy, Hypogammaglobulinemia
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension
The aim of the study is to find out if patients with blood cancers receiving immunoglobulin (Ig) for the purpose of preventing infections can safety stop immunoglobulin after six months of therapy, and take oral antibiotics…
- Trial name
- RATIONALISE (NCT05678621)
- Testing
- trimethoprim-sulfamethoxazole (co-trimoxazole), amoxycillin/clavulanic acid and ciprofloxacin, Immunoglobulins
- Where
- 7 sites in Australia
- Volunteers
- 300 people
- Sponsor
- Monash University
Multiple Myeloma, Secondary Immunodeficiency
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Multiple myeloma is a cancer of the plasma cells in the bone marrow. The main aim of this study is to learn how well the Immune Globulin Infusion (human), 10 percentage (%) (IGI, 10%) can help prevent infections in participants…
- Trial name
- NCT06980480
- Testing
- IGI, 10%
- Where
- 65 sites in United States, Australia and 15 more
- Volunteers
- 183 people
- Sponsor
- Takeda
Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
The main goal of this study is to show that people with certain immune problems (from Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma) get fewer serious infections when they receive Gamunex C through an IV…
- Trial name
- SIGMA (NCT07582432)
- Testing
- Gamunex-C, 10% Injectable Solution
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- Grifols Biologicals, LLC
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
Pancreatic Cancer, Thyroid Cancer
Integrated Cancer Repository for Cancer Research
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer…
- Conditions
- Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer
- Trial name
- iCaRe2 (NCT02012699)
- Where
- 42 sites in United States
- Volunteers
- 999,999 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer)
A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.
This is a multicenter, open-label, randomized (1:1) trial designed to evaluate whether ctDNA-guided interruption of immune-checkpoint inhibitor (ICI) therapy provides comparable survival to standard of care (SoC) continuous ICI…
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Carcinoma), NSCLC
- Trial name
- SIGNAL-IO 301 (NCT07689812)
- Testing
- Signatera Genome ultra-sensitive ctDNA blood test
- Volunteers
- 920 people
- Sponsor
- Natera, Inc.
Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis
National Registry of Rare Kidney Diseases
The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research.
- Conditions
- Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis, AHL Amyloidosis, AL Amyloidosis
- Trial name
- RaDaR (NCT06065852)
- Where
- United Kingdom
- Volunteers
- 35,000 people
- Sponsor
- UK Kidney Association
Hypogammaglobulinemia, Acquired
Immunoglobulin for Hypogammaglobulinemia Due to Chimeric Antigen Receptor T Cell Therapy
Chimeric antigen receptor (CAR) T cells are special immune cells taken from a patient and changed in a lab to help them find and attack cancer cells.
- Trial name
- ICART (NCT06989541)
- Testing
- Immune Globulin Intravenous (Human), 10%, Immune Globulin Subcutaneous (Human), 20% Solution
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University of Alberta
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck Cancer
This Phase 2, open-label, multicenter study will evaluate the safety and preliminary efficacy of axelopran in combination with pembrolizumab in patients with PD-L1 positive recurrent or metastatic head and neck squamous cell…
- Trial name
- MORALE-HN01 (NCT07662720)
- Testing
- axelopran, Pembolizumab
- Volunteers
- 18 people
- Sponsor
- Glycyx Therapeutics
Primary Immunodeficiencies (PID), Secondary Immunodeficiencies (SID)
Assessing Patient Preference for Infusion Systems
This crossover study evaluates patient experiences and preferences between mechanical and electrical infusion pumps for subcutaneous immunoglobulin (SCIg) therapy.
- Trial name
- NCT07189013
- Testing
- Mechanical infusion pump
- Where
- United Kingdom
- Volunteers
- 52 people
- Sponsor
- KORU Medical Systems, Inc.
Cervical Cancer, Human Papillomavirus (HPV) Infection
Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India
Cervical cancer (CC) remains one of the most common malignancies among women in India, with nearly 100,000 women diagnosed annually and over 60,000 preventable deaths annually.
- Conditions
- Cervical Cancer, Human Papillomavirus (HPV) Infection, Human Immunodeficiency Virus (HIV) Infection
- Trial name
- SAKHI (NCT07209917)
- Testing
- SAKHI HPV Intervention, Enhanced Standard of Care (SOC+)
- Where
- 4 sites in India
- Volunteers
- 348 people
- Sponsor
- University of California, Irvine
Secondary Immune Deficiency
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
This is a prospective, multicenter, open-label, single-arm study to assess the efficacy, safety, and pharmacokinetics (PK) of IgPro20 in adults with hematologic malignancies treated with B-cell targeting Chimeric antigen receptor…
- Trial name
- NCT07648264
- Testing
- IgPro20
- Where
- 60 sites in United States, Belgium and 9 more
- Volunteers
- 63 people
- Sponsor
- CSL Behring
Gastric Cancer, Colon Cancer
Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers
This study intends to explore the role of PD1/PDL1 antibody with selective combination of Sintilimab, IBI310 and Lenvatinib in organ preservation in non-metastatic dMMR/MSI-H gastric or colon cancers with mismatch repair…
- Conditions
- Gastric Cancer, Colon Cancer, MSI-H, DMMR Cancer
- Trial name
- NCT06580574
- Testing
- PD1/PDL1 antibody monotherapy, up to 24 weeks, Intensive immunotherapy plus anti-VEGF treatment, up to 24 weeks, Radical surgery
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Peking University
Hematologic Disorders, Hemoglobinopathies
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
This is a treatment guideline for a second or greater allogeneic hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) in patients with non-malignant or malignant diseases.
- Conditions
- Hematologic Disorders, Hemoglobinopathies, Immunodeficiencies
- Trial name
- NCT01666080
- Testing
- Busulfan, Fludarabine, Total body irradiation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Secondary Immunodeficiency (SID)
A Study of Secondary Immunodeficiencies in Adults With Blood Cancers in Kazakhstan Who Have a Weakened Immune System (K-SIDE Study)
Some people with blood cancers (hematologic malignancies) develop a weakened immune system because of their condition or the medicines used to treat it. This is called a secondary immunodeficiency or SID.
- Trial name
- NCT07868107
- Testing
- No Intervention
- Where
- Kazakhstan
- Volunteers
- 200 people
- Sponsor
- Takeda
Primary or Secondary Immune Deficiency Including Immunosuppressive Therapy, Chemotherapy, HIV Infection
Performance of Clinical Metagenomics in Stool and Urine Samples for Unexplained Diseases Diagnostic and Emerging Diseases Surveillance in Immunocompromised Patients
The study is based on the hypothesis that the concomitant use of mNGS in non-invasive samples (stool, urine) could improve the rate of detected pathogens in immunodeficient patients compared with mNGS performed in an invasive…
- Trial name
- SENTINEL (NCT07603453)
- Testing
- Metagenomics
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cushing s Syndrome, Cushing Disease
Adrenal Diseases in the Population of Modena: A Clinical-Epidemiological Database of Patients Referred to the Adrenal Disorders Outpatient Clinic of the Clinical Unit of Endocrinology at the Modena University Hospital (AOU Modena)
Primary Objective: The primary objective of the study is to characterize subjects affected by adrenal disease by collecting medical history data at diagnosis, clinical, bio-humoral, and radiological data, as well as information…
- Conditions
- Cushing s Syndrome, Cushing Disease, Cushing Disease Due to Increased ACTH Secretion, Mild Autonomous Cortisol Secretion (MACS)
- Trial name
- ADRENALINK (NCT07920198)
- Where
- Italy
- Volunteers
- 2,000 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Modena
Multiple Myeloma, Secondary Immunodeficiency (SID)
Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency
In this study, multiple myeloma participants with secondary immunodeficiency (SID) will be treated with HyQvia according to their clinic's standard practice.
- Trial name
- NCT05879757
- Testing
- No Intervention
- Where
- 27 sites in Argentina, Czechia and 9 more
- Volunteers
- 75 people
- Sponsor
- Takeda